Insider · CIK 0001618360
Sessa Capital (Master), L.P.
Files at SABS (SAB Biotherapeutics, Inc.). First filing -, latest -.
Sessa Capital (Master), L.P. files SEC Form 4 as director at SABS (SAB Biotherapeutics, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Sessa Capital (Master), L.P. has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 5 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 29, 2025 | SABS SAB Biotherapeutics, Inc. | MOption exercise Common Stock | +1,740,000 | $1.75 | $3.0M | 2,198,457 | Oct 1, 2025 |
| Sep 29, 2025 | SABS SAB Biotherapeutics, Inc. | MOption exercise Series B Convertible Preferred Stockderivative | -17,400 | - | - | 211,100 | Oct 1, 2025 |
| Jul 22, 2025 | SABS SAB Biotherapeutics, Inc. | AGrant or award Series B Convertible Preferred Stockderivative | +228,500 | - | - | 228,500 | Jul 24, 2025 |
| Jul 22, 2025 | SABS SAB Biotherapeutics, Inc. | AGrant or award Warrants (right to buy)derivative | +228,500 | - | - | 228,500 | Jul 24, 2025 |
| Jul 22, 2025 | SABS SAB Biotherapeutics, Inc. | AGrant or award Warrants (right to buy)derivative | +114,250 | - | - | 114,250 | Jul 24, 2025 |
Questions about Sessa Capital (Master), L.P.
Answered from the filings on this page, as of the latest one.
Is Sessa Capital (Master), L.P. buying or selling?
Sessa Capital (Master), L.P. has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Sessa Capital (Master), L.P.'s past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Sessa Capital (Master), L.P. has 0.
Where does Sessa Capital (Master), L.P. file Form 4?
Sessa Capital (Master), L.P. has filed Form 4 at SABS (SAB Biotherapeutics, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.